Targets › PPP5C
1 program from 1 company in 4 trials: 4 Phase 1; Hematology, Oncology.
Serine/threonine-protein phosphatase that dephosphorylates a myriad of proteins involved in different signaling pathways including the kinases CSNK1E, ASK1/MAP3K5, PRKDC and RAF1, the nuclear receptors NR3C1, PPARG, ESR1 and ESR2, SMAD proteins and TAU/MAPT. Implicated in wide ranging cellular processes, including apoptosis, differentiation, DNA damage response, cell survival, regulation of ion channels or circadian…. (UniProt, P53041)
Open in Phaseline: the race on PPP5C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lixte Biotechnology Holdings | LB-100 Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor; Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor; Serine/threonine-protein phosphatase 5 inhibitor | PPP2CA, PPP2CB, PPP5C | Phase 1 | Myelodysplastic Syndromes; Advanced Soft-tissue Sarcoma; Extensive Stage Lung Small Cell Carcinoma; Metastatic Microsatellite-stable Colorectal Cancer | – |
Myelodysplastic Syndromes (1) Advanced Soft-tissue Sarcoma (1) Extensive Stage Lung Small Cell Carcinoma (1) Metastatic Microsatellite-stable Colorectal Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.